1 / 19

Management of Chronic HCV Infection by PMDs

Management of Chronic HCV Infection by PMDs. Rod Rahimi Osler Journal Club 1-25-12. Outline. Background on Hepatitis C Barriers to treatment ECHO (Extension for Community Healthcare Outcomes) model Cohort trial: PMD v. Specialists Conclusions Time for questions/discussion. Hepatitis C.

varnold
Download Presentation

Management of Chronic HCV Infection by PMDs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club 1-25-12

  2. Outline • Background on Hepatitis C • Barriers to treatment • ECHO (Extension for Community Healthcare Outcomes) model • Cohort trial: PMD v. Specialists • Conclusions • Time for questions/discussion

  3. Hepatitis C • 170 million people worldwide (3%) are hepatitis C positive (3.2 million in the US) cdc.gov

  4. Hepatitis C treatment

  5. Hepatitis C treatment

  6. Hepatitis C treatment • Pegylated interferon and ribavirin are available and cost-effective • HCV genotype 1 cure rate 45% • HCV genotype 2 and 3 cure rate 75%

  7. Are patients receiving treatment? • Antiviral treatment rates are <30% • Even among eligible patients treatment rates range from only 45-75% • Rates even lower in rural areas and prisons • In New Mexico, 40% of the 6000 inmates are infected with HCV. As of 2003 not a single one had received antiviral treatment

  8. Barriers to Treatment • Treatment is currently complex • Most PMDs lack training • Complex side effects from treatment including flu-like symptoms, cytopenias, hemolysis, autoimmunity, depression • In New Mexico, patients had to travel up to 250 miles to the UNM medical center, having to make an average of 18 trips during treatment

  9. The University of New Mexico • The ECHO (Extension for Community Healthcare Outcomes) Model • http://www.youtube.com/watch?feature=player_embedded&v=2lBfyOlL4_s

  10. The ECHO Model

  11. Arora S et al. N Engl J Med 2011;364:2199-2207.

  12. Arora S et al. N Engl J Med 2011;364:2199-2207.

  13. Arora S et al. N Engl J Med 2011;364:2199-2207.

  14. Arora S et al. N Engl J Med 2011;364:2199-2207.

  15. Conclusions • PMDs treating HCV infection with assistance of the ECHO model are as effective in achieving SVR as specialists • No difference in serious adverse events between PMDs and specialists

  16. Critical Appraisal Discussion • What comparison is being made? • Does the comparison make clinical sense? • What are the potential selection biases?

  17. Critical Appraisal Discussion • No comparison group comprising patients treated by PMDs without ECHO • No PMDs treating HCV independently • Unethical to randomize PMDs to treating HCV without ECHO • The study was not large enough to establish equivalence between PMDs with ECHO and specialists

  18. Telemedicine Discussion • Advantages • Increase clinical knowledge among PMDs • Increase clinical access to specialist treatments • Cost-effective • Disadvantages • Delay referrals • Potentially demanding on specialists • Potential for adverse events

  19. References • Arora et al. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. N Engl J Med. 2011 June 9;364(23):2199-2207. • Fried et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. • Swain et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010 Nov;139(5):1593-601. • Kanwal et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007 Dec;46(6):1741-9.

More Related